NasdaqGS:VTRSPharmaceuticals
Viatris’ FDA-Reviewed Weekly Contraceptive Patch Could Be A Game Changer For Viatris (VTRS)
Viatris recently showcased six presentations at the 2026 ACOG Annual Clinical & Scientific Meeting in Washington, highlighting positive Phase 3 efficacy, safety, adhesion, pharmacokinetic and cycle control data for its investigational low-dose estrogen weekly contraceptive patch.
The company also secured FDA acceptance of its New Drug Application for the patch with a July 30, 2026 target action date, underscoring how women’s health innovation is becoming a more visible part of Viatris’...